More than one-fourth of the world’s diabetes patients live in China—and Novo Nordisk wants to give them a better way to ask questions and get information. It’s partnering with Microsoft to create a Chinese-language AI chatbot, set to launch early next year on the Danish drugmaker’s digital patient support platforms.
The artificially intelligent chatbot will help deliver relevant information in both voice and text to the country’s massive diabetes population of 129 million—many of whom face difficulties managing their condition. Fewer than 16% of people control their disease well because of late diagnosis, poor medical attention or just not understanding the best ways to keep the disease in check, Microsoft and Novo Nordisk said in a press release.
Novo Nordisk hopes the chatbot will “provide answers to patients’ everyday questions and allow them to be more aware and prepared to cope with the disease and live a better quality life.”
“Novo Nordisk has witnessed how diabetes has become one of the world’s biggest health challenges,” Christine Zhou, SVP and president of Novo Nordisk Region China, said, adding that “innovations in medicine should be accompanied by a patient-centric philosophy that extends to empowering patients to manage their disease.”
Novo Nordisk is no stranger to AI chatbots. Its American version, Sophia—which is bilingual in Spanish—has been noted as an industry standard. Sophia has been chatting with Novo’s diabetes patients on the company’s Cornerstones4Care website since 2018.
“All industries, including healthcare, are accelerating their pace of digital transformation by using digital technologies to respond to, and recover from, this pandemic,” Alain Crozier, Microsoft’s corporate VP, chairman and CEO of the Greater China Region, said.
Pharma is not alone in embracing AI and chatbots in particular, with an anticipated $4.5 billion invested in chatbots in 2021, according to Opus Research.
by Sharon Klahr Coey
Source: fiercepharma.com
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
